Novo Nordisk is suing telehealth provider Hims & Hers for marketing unapproved, cheaper copies of its Wegovy obesity pill and injections, claiming the compounded drugs infringe on its patents and put patients at risk.

The lawsuit seeks to permanently stop Hims from selling these copycats and to recover damages, as Novo accuses Hims of mass-producing “personalized” medicines illegally.

Hims has defended its practices, calling the lawsuit an attack on Americans’ access to compounded medications, though it has agreed to halt sales amid federal scrutiny.

The dispute comes as Novo works to protect its market share in the booming obesity drug sector and fend off competitors like Eli Lilly and other compounded alternatives, CNBC has reported.

The FDA is also taking action against Hims, including restricting ingredients and referring the company to the Department of Justice for potential violations.